ArticleDiscover oncology2026
Aberrant expression of GBP5 in tumor-infiltrating immune cells as an onco-immunological biomarker in pan-cancer.
Article in Discover oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
backgroundGuanylate binding protein 5 (GBP5) belongs to an interferon (IFN)-inducible subfamily of guanosine triphosphatases (GTPases). GBP5 has been shown to promote NLRP3 inflammasome assembly, thereby playing a key role in innate immunity and inflammation. However, the role of GBP5 in the development of various cancers and its potential as a biomarker in cancer prognosis are still unexplored.
methodsIn this study, we used integrative analysis of multi-omics data, including global gene expression, tumor immune infiltration, biological functions, molecular signatures, diagnostic value of biomarkers and responses to therapies in pan-cancer to evaluate the potential of GBP5 as a biomarker in cancer prognosis.
resultsHere, it is found that GBP5 is aberrantly expressed in the infiltrated immune cells in most cancer types. Furthermore, GBP5 not only responds to external cytokines, but also controls the expression of chemokines and immunomodulators. Consistently, GBP5 expression is positively associated with infiltration levels of immune cells in diverse cancer types. Moreover, GBP5 exhibits robust predictive power for response outcomes of immune checkpoint blockade (ICB) therapy compared to other 21 established biomarkers.
conclusionAltogether, our study strongly suggests that GBP5 is an onco-immunological biomarker with potential value for cancer prognosis and the efficacy prediction of ICB immunotherapy.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.